Medicine and Dentistry
Diseases
100%
Pancreas Cancer
74%
Pancreas Adenocarcinoma
68%
Overall Survival
68%
Neoadjuvant Therapy
64%
Cancer of Unknown Primary Origin
59%
Abdominal Cancer
56%
Metastatic Carcinoma
56%
Neoplasm
55%
Malignant Neoplasm
52%
Primary Tumor
41%
Systemic Therapy
36%
Hazard Ratio
36%
Metastatic Colorectal Cancer
34%
Surgery
34%
Treatment Response
32%
Stomach Adenocarcinoma
29%
Neoadjuvant Chemotherapy
29%
Pembrolizumab
29%
Colorectal Carcinoma
27%
Adjuvant Therapy
25%
Radiation Therapy
25%
Oxaliplatin
24%
Fluorouracil
24%
Arm
22%
Esophagectomy
21%
Gemcitabine
19%
Lymph Node
17%
Anemia
17%
Monoclonal Antibody
16%
Phase II Trials
16%
Proportional Hazards Model
16%
Perineural Invasion
15%
Bevacizumab
15%
Microsatellite Instability
14%
Combined Therapy
14%
Growth Factor Receptor
14%
Chronic Kidney Disease
14%
CA 19-9 Antigen
14%
Intraductal Papillary Mucinous Tumor
14%
Folinic Acid
14%
Advanced Cancer
14%
Esophageal Cancer
14%
Oncolytic Virus
14%
First-Line Chemotherapy
14%
Veliparib
14%
Endothelial Cell Growth Factor
14%
Cardiovascular Risk
14%
Gene Therapy
14%
DNA Mismatch Repair
14%
Keyphrases
Pancreatic Ductal Adenocarcinoma
53%
Neoadjuvant Therapy
49%
Resectable Pancreatic Cancer
44%
Prognostic Value
44%
Cancer of Unknown Primary
44%
Chemotherapy
44%
Overall Survival
40%
Pancreatic Cancer
36%
Metastatic Pancreatic Ductal Adenocarcinoma
33%
Nodal Response
33%
Carbohydrate Antigen 19-9 (CA19-9)
32%
Gastric Cancer
32%
Phase II Study
30%
Metastatic Pancreatic Cancer
30%
Hazard Ratio
30%
Treatment Response
29%
Gastric Adenocarcinoma
29%
Veliparib
29%
Pembrolizumab
29%
Neoadjuvant Chemotherapy
25%
ABT-888
25%
Cancer Cells
25%
Pancreatic Adenocarcinoma
25%
Risk of Death
22%
Metastatic Disease
22%
In Cancer
21%
Systemic Therapy
21%
Primary Tumor
20%
High-risk Features
20%
Immune Checkpoint Inhibitors
20%
Single Center
19%
Pathological Response
19%
Post-resection
19%
Tumor
19%
Combination Therapy
18%
Immunoconjugate
18%
Monoclonal Antibody
18%
Solid Tumors
18%
Objective Response Rate
18%
Radiological Response
17%
Resection Specimen
17%
Disease Response
17%
Clinical Outcomes
17%
Patients with Colorectal Cancer
17%
Biomarker Analysis
17%
5-fluorouracil (5-FU)
17%
Combined Modality Therapy
16%
Chemotherapy Alone
16%
Early Phase Clinical Trials
16%
Tumor Response
16%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
79%
Malignant Neoplasm
72%
Chemotherapy
64%
Pancreas Adenocarcinoma
63%
Diseases
55%
Overall Survival
44%
Pancreas Cancer
44%
Primary Tumor
36%
Metastatic Colorectal Cancer
34%
Monoclonal Antibody
31%
Combination Therapy
28%
Progression Free Survival
26%
Colorectal Carcinoma
24%
Metastasis
22%
Anemia
22%
Maximum Tolerated Dose
21%
Solid Malignant Neoplasm
20%
Pharmacokinetic
19%
Clinical Trial
18%
Phase II Trials
18%
Immune Checkpoint Inhibitor
16%
Bevacizumab
15%
Chronic Kidney Failure
14%
Bortezomib
14%
Artesunate
14%
Sorafenib
14%
Growth Factor Receptor
14%
Cancer of Unknown Primary Site
14%
Antibody Conjugate
14%
Abdominal Cancer
14%
Randomized Clinical Trial
14%
Hormone Cancer Therapy
14%
Folinic Acid
14%
Liver Cell Carcinoma
14%
Pembrolizumab
14%
First-Line Chemotherapy
14%
Oncolytic Virus
14%
Paclitaxel
14%
Proteasome Inhibitor
14%
Lapatinib
14%
Cardiovascular Risk
14%
Endothelial Cell Growth Factor
14%
Ixabepilone
14%
Temozolomide
14%
Gemcitabine
14%
Anticarcinogen
14%
Phosphotransferase Inhibitor
14%
Antiangiogenic Therapy
14%
Immunotherapy
14%
Esophageal Adenocarcinoma
14%